Hayashi, Daichi
Kompel, Andrew J.
Ventre, Jeanne
Ducarouge, Alexis
Nguyen, Toan
Regnard, Nor-Eddine
Guermazi, Ali
Funding for this research was provided by:
Gleamer
Article History
Received: 16 March 2022
Revised: 28 April 2022
Accepted: 28 April 2022
First Online: 6 May 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Our study was approved by the WellCare Group (WCG) institutional review board (approval number 20202256). The need for informed consent was waived because our study was retrospective and all images were totally anonymized and stripped of any clinical information. HIPAA requirements were strictly followed.
: Ali Guermazi is a shareholder of BICL, LLC, and Consultant to Pfizer, Novartis, Regeneron, AstraZeneca, Merck Serono, and TissueGene.JV, ZZ, AD, TN, AT, EL, AP, Albane Grandjean are employees of Gleamer.AD is the Chief Technical Officer and co-founder of Gleamer.NER is the Chief Medical Officer and co-founder of the Gleamer.All other authors have no other conflict of interest to report.